Answers are grounded in this paper and cite their sources.
Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous (s.c.) infusions. Bioavailability was 99%+/-18% after s.c. administration, but peaks were reduced by about (43+/-29 versus 115+/-28 microg/ml) and times to peak were delayed. Simulations based on unbound concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval, suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.
No takes yet. Share an insight, caveat, or question.
Frasca et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: